Press Releases

Date Title and Summary Additional Formats
Toggle Summary MINERVA NEUROSCIENCES TO HOST KEY OPINION LEADER MEETING ON ROLUPERIDONE: A POTENTIALLY NOVEL MECHANISM TO TREAT THE NEGATIVE SYMPTOMS OF SCHIZOPHRENIA
Call at 8:00 a.m. Eastern Time on Tuesday, March 31, 2020 WALTHAM, Mass. , March 24, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet medical needs in the treatment of
View HTML
Toggle Summary MINERVA NEUROSCIENCES UPDATES MARKET ON SHARE PRICE DROP AND TRADING HALT
WALTHAM, Mass. , March 12, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat unmet medical needs of central nervous system (CNS) disorders, wishes to address a sharp reduction
View HTML
Toggle Summary Minerva Neurosciences Reports Fiscal 2019 Fourth Quarter and Year End Financial Results and Business Updates
Company confirms timing of expected top-line results from Phase 3 roluperidone trial in Q2 2020 Management to host conference call today at 8:30 a.m. Eastern Time WALTHAM, Mass. , March 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical
View HTML
Toggle Summary Minerva Neurosciences to Report Fiscal 2019 Fourth Quarter and Year End Financial Results and Business Updates on March 9, 2020
Management to host conference call WALTHAM, Mass. , March 02, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
Toggle Summary Minerva Neurosciences to Host Key Opinion Leader Meeting on Avolition, the Most Central Domain for the Successful Treatment of Negative Symptoms in Schizophrenia
Breakfast meeting to be held on Friday, March 6, 2020 in New York WALTHAM, Mass. , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat unmet medical needs of central
View HTML
Toggle Summary Minerva Neurosciences Announces Completion of Patient Enrollment in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
Data readout expected in the second quarter of 2020 WALTHAM, Mass. , Feb. 05, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet medical needs in the treatment of central
View HTML
Toggle Summary Minerva Neurosciences Announces Completion of Patient Screening in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
Top-line results expected in the second quarter of 2020 WALTHAM, Mass. , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet medical needs in the treatment of central
View HTML
Toggle Summary Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder
MIN-117 study did not meet its primary (MADRS) and key secondary (HAM-A) endpoints MIN-117 was generally well-tolerated with a safety profile comparable to placebo Company to host conference call at 5:00 p.m. today (dial-in information below) WALTHAM, Mass. , Dec.
View HTML
Toggle Summary Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 21, 2019
WALTHAM, Mass. , Nov. 14, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies London
View HTML
Toggle Summary Minerva Neurosciences Reports Third Quarter 2019 Financial Results and Business Updates
WALTHAM, Mass. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the
View HTML